glp1
Orforglipron tracker
Educational reference for Orforglipron. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
36 h
Tmax
4 h
Category
glp1
Also known as: LY3502970
Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist in clinical trials for weight loss and diabetes. Not FDA-approved. Taken orally.
Mechanism
An investigational, orally active non-peptide (small-molecule) GLP-1 receptor agonist. Being non-peptide, it is designed for oral administration without the formulation constraints of peptide GLP-1 agonists.
Research summary
Investigational and not FDA-approved. It has been studied for type 2 diabetes and weight management, with phase 2 and phase 3 results reported in the literature. Larger evaluation continues.
Reported side effects
Gastrointestinal effects (nausea, vomiting, diarrhea) are the most commonly reported in trials, consistent with the GLP-1 class. The full safety profile is not yet established given its investigational status.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Orforglipron phase 2/3 trials (NEJM) · New England Journal of Medicine (2023)search PubMed/NEJM for orforglipron; investigational
- Oral small-molecule GLP-1 agonist reviews · peer-reviewed review articles (2024)investigational; not FDA-approved
A TrackPep egy naplózó alkalmazás. Azt rögzíti, amit megadsz, és soha nem javasol vagy számít ki mennyiségeket.